Core Viewpoint - The company, Rhein Biotech, is planning a change in control and has announced a suspension of trading due to the potential transfer of shares and voting rights by its controlling shareholder, Qin Benjun [1][2]. Group 1: Control Change Announcement - On December 8, the company received a notification from its controlling shareholder, Qin Benjun, regarding the planned change in control [1]. - Qin Benjun intends to transfer part of his shares to Guangzhou Defu Nutrition and will voluntarily relinquish voting rights for some of his shares [2]. - A "Control Change Intent Agreement" has been signed, but specific transaction details are still under negotiation [1][2]. Group 2: Transaction Details - The company plans to issue shares to acquire an 80% stake in Beijing Jinkangpu from Defu Jinkangpu Holdings and Xiamen Defu Jinkangpu Investment Partnership [2]. - The transaction aims to integrate Beijing Jinkangpu into the listed company structure, enhancing business synergies [2]. Group 3: Financial Performance - For the first three quarters of the year, the company reported a revenue of 1.272 billion yuan, representing a year-on-year increase of 8.73% [3]. - The net profit attributable to shareholders was 70.3953 million yuan, showing a year-on-year decline of 30.73% [3].

莱茵生物（002166）12月9日晚间公告，公司于2025年12月8日收到控股股东、实际控制人秦本军的通知，秦本军正在筹划公司控 制权变更事宜。公司股票自2025年12月10日开市起停牌，预计停牌时间不超过10个交易日。 公告显示，秦本军及公司已与本次交易的主要交易对方广州德福营养投资合伙企业（有限合伙）（简称"广州德福营养"）、德福 金康普控股有限合伙企业、厦门德福金普投资合伙企业（有限合伙）分别签署了《控制权变更意向协议》《发行股份购买资产并 募集配套资金意向协议》，协议约定秦本军通过协议转让方式将其所持有的部分公司股份转让给广州德福营养，并签署《表决权 放弃协议》，自愿放弃其所持公司部分股份的表决权。上述事项可能导致公司控股股东及实际控制人发生变更。 同时公司拟向德福金康普控股有限合伙企业和厦门德福金普投资合伙企业（有限合伙）发行股份购买其合计持有的北京金康普食 品科技有限公司（简称"北京金康普"）80%股权，以及向广州德福营养发行股份募集配套资金。 本次交易完成后，北京金康普将成为公司的控股子公司，纳入合并财务报表范围。本次交易不构成重大资产重组及重组上市。 本次交易将北京金康普纳入上市公司体系，双方 ...

Group 1 - The company, Rhine Biology, announced a suspension of trading on December 10, 2025, due to plans for a change in control and the issuance of shares to acquire assets [2][4] - The controlling shareholder, Qin Benjun, is planning to transfer part of his shares and relinquish voting rights, with a control change agreement already signed with key parties [4] - The company intends to acquire 80% of Beijing Jinkangpu's shares through share issuance and raise matching funds from Guangzhou Defu Nutrition [4][5] Group 2 - The transaction aims to integrate Beijing Jinkangpu into the listed company, enhancing synergy in the food and beverage and health product sectors, thereby improving R&D capabilities and market coverage [5] - Rhine Biology specializes in the production of natural health products, focusing on the R&D and production of plant functional ingredients, with over 300 standardized extraction technologies [5] - In the first three quarters of this year, the company reported revenue of 1.272 billion yuan, an increase of 8.73%, while net profit attributable to shareholders fell by 30.73% to 70.3953 million yuan [5]

证券日报网讯 12月9日，安控科技在互动平台回答投资者提问时表示，公司管理团队始终牢记推动公司 做大做强、保障国有投资保值增值的目标，公司围绕以下三个方面开展工作：一是聚焦核心业务攻坚， 深耕工业自动化、油气服务等优势板块，深化与行业头部客户合作，努力拓展高毛利订单，同时收缩非 核心业务，优化资源配置；二是推进降本增效，严控运营成本与费用，梳理供应链体系，提升管理效 率；三是积极对接宜宾当地产业资源，探索与区域内能源、智能制造企业的协同合作，培育新增长点。 根据《深圳证券交易所创业板股票上市规则》，公司将及时披露经营进展。经营改善需经历业务梳理、 市场拓展、效益释放的过程，目前各项措施已逐步落地，公司将全力推进执行，后续进展请以公司指定 平台公告为准。 （编辑 姚尧） ...

Group 1 - The company plans to acquire 81% of Shenzhen 863 New Materials Technology Co., Ltd. for 97.524 million yuan, marking a significant step in its layout within the inspection and certification industry [1][2] - Shenzhen 863, established in 2008, operates as a public technology service platform focusing on inspection and testing, with a history linked to the National 863 Program [1] - The company possesses hundreds of precision testing devices and collaborates with major enterprises like Foxconn, Huawei, and BYD, aiming to create a comprehensive materials research and testing evaluation system [1] Group 2 - The acquisition is expected to integrate the target company's professional talent, technical qualifications, and laboratory management experience, enhancing the company's capabilities in the inspection and certification sector [2] - This asset transfer within the state-owned system is seen as a demonstration of industry significance, promoting the upgrade of inspection services towards specialization and precision [2] - The transaction is pending approval from both parties' shareholders, and the effectiveness of the integration will be closely monitored by the capital market [2]

来源：喜娜AI异动分析 根据喜娜AI异动分析，厦门港务涨停原因可能如下，重大资产重组+业务协同+政策支持： 1、公司正推 进重大资产重组，收购集装箱码头集团70%股权，交易完成后2024年归母净利润预计增长198.43%。目 前该重组已获股东大会通过，处于交易所审核阶段，若成功实施将显著提升公司资产质量和盈利能力。 2、公司集装箱业务与现有散杂货业务形成互补，能够完善港口综合服务产业链，产生业务协同效应。 同时，交易后资产负债率从50.92%降至42.07%，财务结构更加稳健。此外，公司符合国家港口资源整 合政策方向，可享受自贸区等多重政策红利。 3、2025年1 - 8月公司扣非净利润同比增长119.65%，展 现出较好的盈利增长态势。行业方面，近期港口航运板块受到市场关注，部分同概念股票也有活跃表 现，形成板块联动效应。从资金流向看，当日可能有主力资金流入厦门港务，推动股价涨停。 声明：市场有风险，投资需谨慎。本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题， ...

证券日报网讯 12月8日，苏州规划在互动平台回答投资者提问时表示，关于此次公司对东进航科的收 购，是公司基于未来业务长期发展而做出的战略选择，若本次收购完成，东进航科业务将与公司原有业 务形成协同，进而一定程度上增强公司的核心竞争力。 （文章来源：证券日报） ...

中国基金报记者 孙越 赵心怡 临近年底，券商资管大集合产品的公募化改造进入最后的密集操作期。根据2018年资管新规配套法规要求，券商参公大集合应在2025年年 底前完成公募化改造。目前各券商正加速推进产品处置，行业迎来历史性时刻。 移交"兄弟"公募、清盘或转型私募是目前产品处置的三大主流路径，与此同时，"跨集团迁移"等新兴案例也为行业提供了新思路。此外， 在公募牌照申请热潮退去后，券商资管的发展逻辑正从追逐牌照转向深耕能力，以投研实力和业务协同为核心的差异化竞争新阶段已然开 启。 大集合产品改造进入冲刺阶段 【导读】 券商资管公募化改造冲刺，以投研与协同能力突围 对于不符合公募化改造条件或规模较小的产品，只能选择转为私募资管计划或清盘。今年6月，国投证券资管宣布将"安信资管瑞元添利一 年持有期债券型集合资产管理计划"转为私募资管计划。此前，东海证券、平安证券、光大证券都有产品因规模较小而选择清盘。 目前，券商大集合产品改造主要有三种路径：管理人变更、清盘或转型私募。 在主流路径之外，近期市场上还出现了"跨集团迁移"案例，部分券商选择将旗下产品移交至无直接股权关联的第三方公募基金管理。 将大集合产品移交至同一股 ...

Core Viewpoint - Huakang Co., Ltd. has decided to terminate the planned acquisition of 100% equity in Yuxin Sugar Alcohol due to significant changes in the market environment since the initial planning phase, despite the transaction being in progress for over a year [2][4]. Group 1: Transaction Details - The company intended to acquire Yuxin Sugar Alcohol for a total price of 1.098 billion yuan through a combination of issuing shares and cash payments [2]. - The assessment value of Yuxin Sugar Alcohol's 100% equity as of December 31, 2024, was 1.101 billion yuan, reflecting an increase of 556 million yuan and an appreciation rate of 102.01% [2][3]. Group 2: Company Performance - Huakang Co., Ltd. has faced a situation of increasing revenue without corresponding profit growth, with a revenue increase of 0.93% to 2.808 billion yuan in 2024, while net profit decreased by 27.72% to 268 million yuan [4]. - In the first three quarters of 2025, the company reported a revenue of 2.959 billion yuan, a year-on-year increase of 40.52%, but net profit declined by 9.91% to 168 million yuan [4]. Group 3: Industry Context - The company and Yuxin Sugar Alcohol are recognized as leading firms in the production and technology of xylitol, with the acquisition aimed at enhancing market competitiveness and operational efficiency [4]. - The industry is currently facing challenges, including a major customer of Yuxin Sugar Alcohol experiencing a debt crisis, which may impact the market dynamics [4].

编号：2025-011 | | 特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动类 | □媒体采访 □业绩说明会 | | 别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他（请文字说明其他活动内容） | | | 参与单位： 东吴证券、易方达 | | 活动参与人员 | 上市公司接待人员： | | | 董事会秘书 邱天 | | | 公司 团队工作人员 IR | | 时间 | 年 月 日下午 2025 12 4 | | 地点 | 公司会议室 | | 形式 | 线上会议 | | | 1.公司 2025 年三季度经营情况如何？ | | | 答：2025 年三季度公司经营稳步向上，营业收入 亿 622.11 | | | 元，同比增长 4.22%；归母净利润 3.84 亿元，同比增长 31.41%； | | | 扣非归母净利润 亿元，同比增长 36.83%。实现营收、利润 3.79 | | | 双增长，公司管理层对公司长期发展充满信心，将聚焦于公司经 | | 交流内容及具体问 | 营与战略落地。 | | 答记录 | 2.公司进入通用技术集团后有哪些变化？ | | | ...